High furosemide dose has detrimental effects on survival of patients with stable heart failure

Hellenic Journal of Cardiology

Volumn 56, Issue 2, 2015, Pages 154-159

  Kapelios, Chris J ^a   Kaldara, Elisabeth ^a   Ntalianis, Argyrios ^a   Sousonis, Vasilios ^a   Repasos, Evangelos ^a   Sfakianaki, Titika ^a   Vakrou, Styliani ^a   Pantsios, Chris ^a   Nanas, John N ^a   Terrovitis, John V ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chronic heart failure; Diuretics; Mortality; Prognosis; Risk factors

Indexed keywords

FUROSEMIDE; DIURETIC AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; DETERIORATION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOKALEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONISCHEMIC CARDIOMYOPATHY; OXYGEN CONSUMPTION; RETROSPECTIVE STUDY; SURVIVAL RATE; AGED; CHEMICALLY INDUCED; DOSE RESPONSE; GREECE; INCIDENCE; KIDNEY FUNCTION TEST; MORTALITY; PATHOPHYSIOLOGY; PATIENT ACUITY; PROCEDURES; PROGNOSIS; RISK FACTOR; SURVIVAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; FUROSEMIDE; GREECE; HEART FAILURE; HUMANS; HYPOKALEMIA; INCIDENCE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT ACUITY; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TIME;

EID: 84927914233     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012; 125: e2-e220.
2. Butler J, Fonarow GC, Gheorghiade M. Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. JAMA. 2013; 310: 2035-2036.
3. Adams KF Jr, Fonarow GC, Emerman CL, et al; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149: 209-216.
4. Lindenfeld J, Albert NM, Boehmer JP, et al; Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010; 16: e1-194.
5. Routier G. [Acute pulmonary edema in carbon monoxide poisoning. Value of intravenous acetazolamide]. J Sci Med Lille. 1962; 80: 352-354.
6. Ledingham JG. Ethacrynic acid parenterally in the treatment and prevention of pulmonary oedema. Lancet. 1964; 1: 952-954.
7. Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population-based meta-analysis of furosemide pharmacokinetics. Biopharm Drug Dispos. 2014; 35: 119-133.
8. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14: 803-869.
9. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128: e240-327.
10. Neuberg GW, Miller AB, O’Connor CM, et al; PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002; 144: 31-38.
11. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006; 97: 1759-1764.
12. Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J. 2010; 160: 264-271.e1.
13. Mielniczuk LM, Tsang SW, Desai AS, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008; 14: 388-393.
14. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005; 365: 417-430.
15. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985; 103: 1-6.
16. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987; 57: 17-22.
17. Tomaschitz A, Pilz S, Ritz E, et al. Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J. 2011; 32: 2642-2649.
18. Girerd N, Pang PS, Swedberg K, et al; for the EVEREST investigators. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail. 2013; 15: 1228-1235.
19. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003; 42: 705-708.
20. Packer M, Bristow MR, Cohn JN, et al; for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349-1355.
21. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327: 685-691.
22. Zannad F, McMurray JJ, Krum H, et al; for the EMPHASISHF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21.
23. Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SE. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol. 2011; 58: 375-382.
24. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and Risk of Arrhythmic Death in Patients With Left Ventricular Dysfunction. Circulation. 1999; 100: 1311-1315.
25. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004; 147: 331-338.
26. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000; 35: 681-689.
27. Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med. 2008; 36: S75-88.
28. Alexopoulos GP, Anastasiou-Nana MI, Rapti AC, et al. Lowering of furosemide dosage after clinical stabilization in patients with congestive heart failure. Acta Cardiol. 2003; 58: 513-517.